SEATTLE, July 15, 2022 – According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).

Genome engineering is a technique in which a Deoxyribonucleic acid (DNA) is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted by the scientist in genome engineering for the development of novel technologies in genome engineering. For instance, in October 2017, Synthego Corporation launched a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Several genome technologies are under trial for treatment of chronic diseases, and are expected to receive approvals over the forecast period.

Key Trends and Analysis of the Global Genome Engineering Market:

Strategic collaboration of key players in market for genome engineering technologies is also expected to positively affect market growth. For instance, January 2018, two key players, Sangamo Therapeutics Inc. and Pfizer Inc. entered into a strategic collaboration for development of potential gene therapy using zinc finger protein transcription factors (ZFP-TFs), to treat amyotrophic lateral sclerosis (ALS).

Coherent Market Insights Logo
Coherent Market Insights

Market Dynamics

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period. Key players in market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. would use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide ribonucleic acid (RNA) products for CRISPR genome engineering.

Request Sample Copy of this Report @

Key Market Takeaways:

Global genome engineering market is expected to exhibit a CAGR of 14.3% during the forecast period due to increasing research and development genome engineering technology. For instance, in February 2022, according to data published by National Center for Biotechnology Information, using gene editing technologies, the sequence in the human genome can be precisely engineered to achieve a therapeutic effect. The ability to make site-specific modifications to the human genome, has invoked a paradigm shift in gene therapy by use of ZFN-mediated gene editing for human gene therapy.

Among technologies, the CRISPR segment is expected to dominate the segment growth over the forecast period, owing to increased research and development activities for advancing genome engineering by key players in market. For instance, in October 2019, in a new study published in Proceedings of the National Academy of Sciences (PNAS), scientists present a new addition to the promising CRISPR toolkit called CRISPR-BEST. This tool operates with an efficient method to create mutations in actinomycetes without requiring a Deoxyribonucleic Acid (DNA) double-stranded break. Although CRISPR-Cas9 tools dramatically simplified the genetic manipulation of actinomycetes, significant concerns of genome instability caused by the DNA double-strand breaks (DSBs) and common off-target effects remained. To address these concerns, CRISPR-BEST was developed, a DSB-free and high-fidelity single-nucleotide–resolution base editing system for Streptomyces.

Key players operating in the global genome engineering market include:

  • Thermo Fisher Scientific Inc.,
  • CRISPR Therapeutics
  • AG, Intellia Therapeutics, Inc.,
  • Editas Medicine, Inc.,
  • Sangamo Therapeutics, Inc.,
  • Bluebird Bio, Inc.,
  • Cellectis S.A.
  • Merck Group.

Detailed Segmentation:

Global Genome Engineering Market, By Technology:

  • ZFN
  • Others

Global Genome Engineering Market, By Application:

  • Cell Line Engineering
  • Genetic Engineering

Global Genome Engineering Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Research Institutes
  • Contract Research Organization

Global Genome Engineering Market, By Region:

  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By Country:
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa